Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sera from eleven patients bearing osteogenic sarcomas were tested for reactivity against autologous and allogeneic normal and tumor cells using a sensitive microcytotoxicity assay. Following absorption with human fetal tissue cultured lines, sera from all 11 patients lost reactivity to autologous and allogeneic normal fibroblasts in culture. However, sera from four patients retained reactivity against both autologous and allogeneic osteogenic sarcoma, sera from five patients retained reactivity to allogeneic but not autologous tumor, and sera from two patients lost all reactivity to tumor. Sera from nine normal individuals did not react with either normal or osteogenic sarcoma cells after fetal cell absorption. Thus it appears that nine of 11 patients bearing osteogenic sarcoma contained antibody to a common tumor-associated antigen. This tumor-associated antigen appears to be expressed on tumor cells and not normal cultured cells, and reactivity to it is present in tumor-bearing but not normal individuals.
 ...
PMID:Serologic analysis of human tumor antigens. II. Reactivity of sera from eleven osetogenic sarcoma patients against autologous and allogeneic tumor cells. 28 77

The clinical, radiological and pathological features of two cases of an osteogenic tumour with long survival are described. The tumours have the histological pattern of benign osteoblastoma with other more cellular and aggressive features suggestive of a low grade osteosarcoma. They are locally invasive but the absence of metastases indicates that separation from both entities is justified clinically and pathologically. The term aggressive osteoblastoma is suggested.
 ...
PMID:Aggressive osteoblastoma. 46 45

A single intramedullary administration of 4-nitroquinoline 1-oxide (4-NQO) into the mandible in 32 rabbits induced 21 cases of osteogenic sarcoma (65.6%), 5 chondrosarcoma (15.6%), 2 fibrosarcomas, and 3 cementoblastomas. None of the tumors appeared until the 3rd month after the treatment. From the 4th to 6th month, early stages of osteogenic tumors were seen. In the late stadium, from 7th to 12th month, tumors showed prominent proliferation and invasion to the oral cavity and surrounding areas. Metastasis to the lung and liver was found in 2 cases of osteogenic sarcoma.
 ...
PMID:Experimental production of osteogenic sarcoma of the mandible in rabbits with 4-nitroquinoline 1-oxide. 80 98

A bone-inducing factor was detected in murine osteosarcoma and its cultured cells. The factor was partially purified from the osteosarcoma and its biological properties were examined. The ectopic formation of the bone with hematopoietic marrow was observed in situ histologically 4 weeks after inoculation of the cell-free material intramuscularly or subcutaneously. Non-osteogenic tumors do not produce this factor. This factor seems to be a protein which is relatively resistant to heating yet labile to mechanical shaking.
 ...
PMID:Osteogenic induction by cell-free material from murine osteosarcoma and its cultured cell line. 81 Mar 84

The bone inducing factor derived from BF osteosarcoma was purified in the following manner. Step 1. The sarcoma, grown in CBA mice, was excised and lyophilized. Step 2. The powder was washed with chilled acetone. Step 3. The acetone-treated powder was then homogenized with chilled distilled water. Step 4. Washing with 0.15M KCl. Step 5. The precipitate was incubated in in 0.2 N NH2OH, pH7.0, for 48 H at 25 degrees. After Step 5, the bone-forming activity showed a slight increase; however, the factor remained insoluble. The properties of the factor were as follows. The factor is relatively relatively heat stable; the osteogenic activity survived the treatment at 75 degrees for 15 min or at 55 degrees for 19 h. The activity was easily lost by mechanical shaking. Incubation with DNase, RNase, neuraminidase, chondroitinase ABC and beta-galactosidase left the osteogenic activity intact, but treatment with either pronase or collagnease destroyed this activity. The results suggest that the factor may be a protein. The activity was seen with the lyophilized BF osteosarcoma cells (without matrix), and it is probable that the factor was exclusively synthesized in the cells. The bone formation, observed across a millipore filter when living BF osteosarcoma enclosed in a millipore chamber was implanted in mice, suggests the synthesis and secretion of the factor from the cells.
 ...
PMID:Studies on a factor responsible for new bone formation from osteosarcoma in mice. 105 58

The role of radiotherapy and adjuvant chemotherapy in the primary treatment of osteogenic sarcomas and of Ewing's sarcoma is reviewed. In osteosarcoma radiotherapy can take the form of prophylactic total irradiation of the lung, but preoperative irradiation of the primary tumor has not proved successful. On the other hand, in Ewing's sarcoma primary and local irradiation is the therapy of choice, and is followed by adjuvant polychemotherapy over a long period.
 ...
PMID:[The role of radiotherapy in the treatment of malignant bone tumors (author's transl)]. 106 Sep 7

A study of 102 osteogenic sarcomas of the bone surface revealed that 79 were parosteal osteogenic sarcomas. Roentgenographically, these 79 were dense, lobulated lesions attached by a broad base to underlying bone, usually the lower femoral shaft. Histologically, they were low-grade osteosarcomas. The other 23 lesions (periosteal osteogenic sarcoma) usually involved the upper tibial shaft and presented as small radiolucent lesions on the surface, with formation of spicules of bone perpendicular to the bone shaft. Histologically, these 23 were relatively high-grade, predominantly chondroblastic osteogenic sarcomas. Thirteen of the 23 patients were males, and most were in the second decade of life. Of five patients who had excision of the tumor, two had recurrence. Seven of 13 patients who underwent amputation initially were alive without disease at last follow-up. Only 4 of the 23 patients have dies of metastatic disease.
 ...
PMID:Periosteal osteogenic sarcoma. 106 59

Juxtacortical osteosarcoma should be considered a very rate distinctive entity under all malignant bone tumors. The tumor has a remarkable tendency to grow from the periostal tissues peripherally with a usually marked degree of ossification without primary medullary involvement. It's different und characteristic behavior in clinical, roentgenographic and microscopic findings from that of other types of bone-forming sarkomas is discussed by means of a just treated case. In contrast to osteogenic osteosarcoma the prognosis for early well treated juxtacortical osteosarcoma is much better.
 ...
PMID:[Juxtacortical osteosarcoma (author's transl)]. 106 68

Of approximately 1,999 cases of osteogenic sarcomas at the Mayo Clinic, 25 were diagnosed as telangiectatic osteogenic sarcomas. Of the 25 patients involved, 16 were males and 9 were females, and their ages ranged from 6 to 49 years. Six patients had had pathologic fracture. The lesions were typically located centrally and usually in the distal femur or proximal humerus and roentgenographically were large and purely lytic with destruction of cortex. Grossly, the lesions were cystic and contained clotted blood. Histologically, cystic spaces that contained blood were lined with anaplastic spindle cells and benign giant cells; sometimes, there were so few malignant cells that diagnosis was difficult. Usually, fine, lacelike osteoid was present. Of the 25 patients, 23 have died of metastatic disease, and another has developed pulmonary metastasis 11 months after amputation. Only one patient has survived for more than five years; however, he has developed pneumothorax. Data from this series suggest that the outlook in telangiectatic osteogenic sarcoma is more bleak than in conventional osteosarcoma.
 ...
PMID:Telangiectatic osteogenic sarcoma. 106 3

The electron-microscopy investigation of osteogenic sarcomas of the osteoplastic type made it possible to identify 4 types of cells with a various ultrastructure. The cells of osteogenic sarcoma retain the ultrastructural specificity of skeletogenous cells and some features of tissue organization. This confirms once more the statement that osteogenic sarcoma is a derivative of the precursor of skeletogenous cells which underwent a tumour transformation.
 ...
PMID:[Electron microscopic study of cell elements and interstitial substance of osteogenic carcinoma]. 107 Sep 50


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>